Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.Robert Hans Ingemar Andtbacka, Kenneth F. Grossmann, Adil Daud et al.|Journal of Clinical Oncology|2017Cited by 55
Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.Robert L. Ferris, Yukihiro Nishiyama, Neil D. Gross et al.|Journal of Clinical Oncology|2014Cited by 30
Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.Robert Hans Ingemar Andtbacka, Kenneth F. Grossmann, Maki Tanaka et al.|Journal of Clinical Oncology|2016Cited by 19